Idiopathic pulmonary fibrosis (IPF) is a deadly progressive lung disease without an effective standard treatment approach. Because of the complexity and uncertainties of IPF treatment, therapeutic decisions need to be tailored to the individual patient, after discussing the potential benefits and pitfalls. Pirfenidone has been approved for the treatment of IPF in many countries, but is not recommended as a first-choice therapy by current guidelines because of the lack of a definite efficacy.

Randomized controlled trials represent a valid choice for patients with IPF, and their completion is important in improving both survival and quality of life.

Clin Chest Med. 2012 Mar;33(1):85-94
Authors: Cerri S, Spagnolo P, Luppi F, Richeldi L
Read Full Article